CL2008003771A1 - Sistema de administracion de rna de interferencia (rnai) que comprende una molecula de rnai unida a un peptido penetrador de celulas; metodo para tratar o prevenir un trastorno ocular en un paciente. - Google Patents

Sistema de administracion de rna de interferencia (rnai) que comprende una molecula de rnai unida a un peptido penetrador de celulas; metodo para tratar o prevenir un trastorno ocular en un paciente.

Info

Publication number
CL2008003771A1
CL2008003771A1 CL2008003771A CL2008003771A CL2008003771A1 CL 2008003771 A1 CL2008003771 A1 CL 2008003771A1 CL 2008003771 A CL2008003771 A CL 2008003771A CL 2008003771 A CL2008003771 A CL 2008003771A CL 2008003771 A1 CL2008003771 A1 CL 2008003771A1
Authority
CL
Chile
Prior art keywords
rnai
patient
treating
preventing
delivery system
Prior art date
Application number
CL2008003771A
Other languages
English (en)
Inventor
Jon E Chatterton
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of CL2008003771A1 publication Critical patent/CL2008003771A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Sistema de administración de RNA de interferencia (RNAI) que comprende una molécula de RNAI unida a un péptido penetrador de células; método para tratar o prevenir un trastorno ocular en un paciente.
CL2008003771A 2007-12-18 2008-12-17 Sistema de administracion de rna de interferencia (rnai) que comprende una molecula de rnai unida a un peptido penetrador de celulas; metodo para tratar o prevenir un trastorno ocular en un paciente. CL2008003771A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1447207P 2007-12-18 2007-12-18

Publications (1)

Publication Number Publication Date
CL2008003771A1 true CL2008003771A1 (es) 2009-08-07

Family

ID=40405152

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003771A CL2008003771A1 (es) 2007-12-18 2008-12-17 Sistema de administracion de rna de interferencia (rnai) que comprende una molecula de rnai unida a un peptido penetrador de celulas; metodo para tratar o prevenir un trastorno ocular en un paciente.

Country Status (6)

Country Link
US (4) US7879813B2 (es)
AR (1) AR069704A1 (es)
CL (1) CL2008003771A1 (es)
TW (1) TW200932274A (es)
UY (1) UY31543A1 (es)
WO (1) WO2009079635A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
KR20100061792A (ko) * 2007-10-01 2010-06-09 알콘 리서치, 리미티드 안 질환을 치료 또는 예방하기 위한 간섭 ｒｎａ 분자의 자기-상보적 ａａｖ 매개 전달
AR069704A1 (es) 2007-12-18 2010-02-10 Alcon Res Ltd Sistema de administracion de rnai de interferencia y usos del mismo
CA3032185C (en) 2010-07-13 2021-08-03 Council on Postsecondary Education, State of Rhode Island and Providence Plantations Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
EP2600900A4 (en) * 2010-08-06 2014-11-19 Univ Illinois SUPRAMOLECULAR MULTIPLEX AGGREGATES FOR THE NONVIRAL OUTPUT OF GENETIC MATERIALS
WO2012149515A2 (en) * 2011-04-29 2012-11-01 Northwestern University Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
US20130178421A1 (en) 2012-01-06 2013-07-11 Alcon Research, Ltd. Interfering rna delivery system and uses thereof
US10723806B2 (en) 2012-02-27 2020-07-28 Riken Method of introducing nucleic acid into plant cells
KR102206573B1 (ko) 2013-03-15 2021-01-25 테출론 인코포레이티드 스타필로코커스 아우레우스 감염의 치료를 위한 안티센스 분자
CA2906663A1 (en) 2013-03-15 2014-09-18 Techulon Inc. Antisense molecules for treatment of staphylococcus aureus infection
WO2014166500A2 (en) 2013-04-10 2014-10-16 Skau Aps Peptides having immune suppresive domains for transfection
WO2014169264A2 (en) 2013-04-11 2014-10-16 The Board Of Trustees Of The University Of Illinois Nanoparticle mediated delivery of sirna
EP3253777B9 (en) * 2015-02-04 2021-11-17 United Arab Emirates University Rvg derived peptides
EP3334831A1 (en) * 2015-08-13 2018-06-20 Forrest Innovations Ltd. Formulations and compositions for delivery of nucleic acids to plant cells
JP2019515654A (ja) 2016-03-16 2019-06-13 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 肥満及び／又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物
EP3500581A4 (en) 2016-08-17 2021-10-06 Solstice Biologics, Ltd. POLYNUCLEOTIDE CONSTRUCTS
US11225507B2 (en) 2017-01-25 2022-01-18 The Board Of Trustees Of The University Of Illinois Conformation switchable antimicrobial peptides and methods of using the same
EP3645546A4 (en) 2017-06-30 2021-12-01 Solstice Biologics, Ltd. CHIRAL PHOSPHORAMIDITIS AUXILIARIES AND THEIR METHODS OF USE
CN110790829B (zh) * 2017-12-19 2022-08-02 北京泽勤生物医药有限公司 pHLIP胞外段作为抗原制备的抗体在制备抗肿瘤药物中的应用
CN113943778A (zh) * 2020-07-17 2022-01-18 通用电气医疗集团股份有限公司 用于核酸检测的分子探针及其制备方法和用途
CN116670293A (zh) * 2020-12-16 2023-08-29 先锋国际良种公司 昆虫细胞内细胞穿透肽介导的rna转导

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AU2354700A (en) * 1998-12-11 2000-06-26 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
MXPA06012605A (es) * 2004-05-04 2006-12-15 Nastech Pharm Co Composiciones y metodos para mejorar el suministro de acidos nucleicos en celulas y para modificar la expresion de genes objetivo en celulas.
US20080199960A1 (en) * 2004-05-13 2008-08-21 Juliano Rudolph L Methods for the Delivery of Oligomeric Compounds
WO2006046978A2 (en) 2004-06-28 2006-05-04 Argos Therapeutics, Inc. Cationic peptide-mediated transformation
ATE505540T1 (de) * 2004-11-16 2011-04-15 Qiagen Gmbh Genabschaltung (gene silencing) durch hybride sens-dna und antisens-rna konstrukte, gekoppelt an ein peptid zur erleichterten aufnahme in zellen
TWI401316B (zh) 2004-12-23 2013-07-11 Alcon Inc 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
TW200639253A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
KR20080018858A (ko) 2005-03-11 2008-02-28 알콘, 인코퍼레이티드 녹내장 치료용 플리즐 관련 단백질―１의 ＲＮＡⅰ－중재저해
US20070128116A1 (en) * 2005-07-27 2007-06-07 Wang Zheng J Multifunctional core for molecular imaging and targeted delivery of macromolecules and drugs
EP1934360A2 (en) * 2005-10-14 2008-06-25 Nastech Pharmaceutical Company Inc. Compounds and methods for peptide ribonucleic acid condensate particles for rna therapeutics
US7579318B2 (en) * 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2007067733A2 (en) * 2005-12-09 2007-06-14 Massachusetts Institute Of Technology Compositions and methods to monitor rna delivery to cells
AR057252A1 (es) 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
TW200731980A (en) 2005-12-29 2007-09-01 Alcon Mfg Ltd RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
WO2008022046A2 (en) * 2006-08-18 2008-02-21 Nastech Pharmaceutical Company Inc. Dicer substrate rna peptide conjugates and methods for rna therapeutics
AR069328A1 (es) * 2007-11-15 2010-01-13 Alcon Mfg Ltd Liberacion de rna interferente corto o sirna, intermediada por receptor de lipoproteina de baja densidad
AR069704A1 (es) * 2007-12-18 2010-02-10 Alcon Res Ltd Sistema de administracion de rnai de interferencia y usos del mismo

Also Published As

Publication number Publication date
US20110082092A1 (en) 2011-04-07
US20090156470A1 (en) 2009-06-18
UY31543A1 (es) 2009-05-29
US9233170B2 (en) 2016-01-12
US20140135267A1 (en) 2014-05-15
TW200932274A (en) 2009-08-01
US20160095937A1 (en) 2016-04-07
WO2009079635A1 (en) 2009-06-25
US8664375B2 (en) 2014-03-04
US9795684B2 (en) 2017-10-24
AR069704A1 (es) 2010-02-10
US7879813B2 (en) 2011-02-01

Similar Documents

Publication Publication Date Title
CL2008003771A1 (es) Sistema de administracion de rna de interferencia (rnai) que comprende una molecula de rnai unida a un peptido penetrador de celulas; metodo para tratar o prevenir un trastorno ocular en un paciente.
BRPI0822100A2 (pt) Método e sistema para administrar automaticamente processos no desenvolvimento paralelo de um aplicativo por uma interface de usuário gráfica, sistema de desenvolvimento de aplicativo de computador, e, meio legível por computador de instruções
BRPI0913300A2 (pt) composto, processo para o preparo e uso do mesmo, método de tratamento de infecção bacteriana em um animal, e, composição farmacêutica.
WO2010036918A3 (en) Intracellular dna receptor
BR112012021522A2 (pt) bráquete ortodôntico para um sistema ortodôntico, sistema de bráquete ortodôntico, kit ortodôntico, processo para fabricar um bráquete ortodôntico e método para tratar a mordida de um paciente humano
BRPI0920253A2 (pt) dispositivo de agulha cirúrgica, sistema de agulha cirúrgica, e, método para usar um dispositivo de agulha cirúrgica.
BRPI0717480A2 (pt) Método e sistema para tratamento de um alimentação de hidrocarboneto, e, composição de hidrocarboneto.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
BRPI0922205A2 (pt) "aparelho de implantação de fibra ótica em unidade de múltiplas residências e métodos para usar o mesmo".
CL2011000814A1 (es) Uso de auna mikacina liposomal que comprende un lipido y amikacina para preparar un medicamento util para el tratamiento de un desorden pulmonar en un paciente.
EP3323405C0 (en) SYSTEM AND METHOD FOR DISPENSING MEDICATION
BRPI0811534A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticametne aceitável do mesmo.
BRPI0913543A2 (pt) sistema de tratamento com pressão reduzida, distribuidor de pressão reduzida para aplicar o tratamento com pressão reduzida a um sítio de tecido, distribuidor para aplicar um tratamento com pressão reduzida a um sítio de tecido subcutâneo e método para aplicar a pressão reduzida a um sítio de tecido
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
BR112012005131A2 (pt) sistema e método para intensificar um processo de tratamento de águas residuais.
BRPI0817961A2 (pt) Método para tratar uma formação subterrânea, e, fluido de tratamento
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
EA201490385A1 (ru) Молекулы для селективной доставки и способы их доставки
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
ATE534378T1 (de) Titrierung von tapentadol
BRPI0912426A2 (pt) método executado por computador, computador, e sistema para uso com poço
BR112012007241A2 (pt) compostos , composição farmacêutica, método para tratar desordens, uso dos compostos, medicamento, método para selecionar inibidores com pequenas moléculas de pcsk9 e pequenas moléculas